SETD2 and pancreatic endocrine carcinoma: For example, the SETD2 tumor suppressor is frequently mutated subclonally in clear cell renal cell carcinomas, as observed previously in multi-region sequencing experiments (Gerlinger et al., 2012), and in pancreatic neuroendocrine cancers.